Biopure’s Hemopure BPAC Review To Be Closed-Door
This article was originally published in The Pink Sheet Daily
Executive Summary
The day before Biopure's July 14 review, FDA's Blood Products Advisory Committee will discuss Nabi's Nabi-HB immunoglobulin for hepatitis B.
You may also be interested in...
FDA Closed-Door Hemopure Meeting Violates Advisory Committee Act, Cries Wolfe
Public Citizen is seeking a temporary restraining order against FDA’s Blood Products Advisory Committee closed-door review of Biopure’s oxygen therapeutic.
FDA Closed-Door Hemopure Meeting Violates Advisory Committee Act, Cries Wolfe
Public Citizen is seeking a temporary restraining order against FDA’s Blood Products Advisory Committee closed-door review of Biopure’s oxygen therapeutic.
Biopure Submits Hemopure Application In The U.K.
The company says it targeted the United Kingdom before the rest of the EU because of the country's "unique blood banking issues."